SCHEMBL4801993

SCHEMBL4801993

CCCCCCOc1ccc(C(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.64
NR5A1 Q13285 1/20 0.56
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
SLC2A1 P11166 1/20 0.54
LMNA P02545 2/20 0.54
MMP9 P14780 1/20 0.54
MMP8 P22894 1/20 0.54
MMP13 P45452 1/20 0.54
GPR88 Q9GZN0 1/20 0.53
PLA2G4B P0C869 1/20 0.53
MLNR O43193 1/20 0.51
NR1I2 O75469 1/20 0.51
ESR1 P03372 1/20 0.51
NR3C1 P04150 1/20 0.51
PGR P06401 1/20 0.51
ADRB2 P07550 1/20 0.51
CHRM2 P08172 1/20 0.51
ADRB1 P08588 1/20 0.51
HTR1A P08908 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL382629 1.00 LTA4H (0.64) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL4798970 1.00 LTA4H (0.64) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL382172 1.00 LTA4H (0.64) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL5820215 1.00 LTA4H (0.64) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL5819935 1.00 LTA4H (0.64) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL5814534 1.00 LTA4H (0.64) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL13098201 0.95 LTA4H (0.63) LTA4HSLC2A1GPR88MLNRNR1I2
SCHEMBL5819934 0.94 LTA4H (0.57) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL5820374 0.94 LTA4H (0.57) LTA4HNR5A1TP53TSHRSLC2A1
SCHEMBL5816104 0.94 LTA4H (0.57) LTA4HNR5A1TP53TSHRSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345163-B2 Process for separating and deprotecting oligonucleotides QUIATECH AB (SE) 2008-03-18 US claimed
WO-2006132588-A1 METHOD FOR THE PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES CONTAINING ONE OR SEVERAL LABELS QUIATECH AB (SE) 2006-12-14 WO claimed
CN-1678618-A Process for separating and deprotecting oligonucleotides QUIATECH AB (SE) 2005-10-05 CN claimed
EP-1546166-A1 PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES Quiatech AB (SE) 2005-06-29 EP claimed
WO-2004020449-A1 PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES QUIATECH AB (SE) 2004-03-11 WO claimed
US-20040044195-A1 Process for separating and deprotecting oligonucleotides QUIATECH AB (SE) 2004-03-04 US claimed
US-7345163-B2 Process for separating and deprotecting oligonucleotides QUIATECH AB (SE) 2008-03-18 US disclosed
WO-2006132588-A1 METHOD FOR THE PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES CONTAINING ONE OR SEVERAL LABELS QUIATECH AB (SE) 2006-12-14 WO disclosed
CN-1678618-A Process for separating and deprotecting oligonucleotides QUIATECH AB (SE) 2005-10-05 CN disclosed
EP-1546166-A1 PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES Quiatech AB (SE) 2005-06-29 EP disclosed
WO-2004020449-A1 PROCESS FOR SEPARATING AND DEPROTECTING OLIGONUCLEOTIDES QUIATECH AB (SE) 2004-03-11 WO disclosed
US-20040044195-A1 Process for separating and deprotecting oligonucleotides QUIATECH AB (SE) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044195-A1 Process for separating and deprotecting oligonucleotides RNGTT, NSUN2, DCLRE1B LTA4H 3433/4885NR5A1 2824/4885TP53 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.